Forus Raises $150M Series C for AI Medication Access

A prescription can leave a doctor's screen in seconds and still spend weeks traveling through insurer rules, assistance programs, pharmacy routing, documents, calls, and faxes. Forus is raising capital against the belief that this administrative journey can become a national AI-managed network instead of a separate negotiation for every patient.

On September 8, 2026, Forus announced a $150M Series C at a $3B valuation, led by Bain Capital Ventures. Every existing institutional investor reinvested, according to the company, including Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Avra, Human Capital, Neo, Vast Ventures, and SV Angel.

The financing takes Forus above $300M in total disclosed funding only 4 months after the New York company introduced its new name and reported a valuation around $1B. The money is meant to extend Forus into more medical specialties and care settings, expand its technology, and build the team required to support growing demand.

The useful part of this story sits beyond the valuation. Forus gives its medication-access product to providers and patients for free, then builds commercial value with biopharma companies that need better visibility into how treatments move from development and approval into real-world use. The Series C is financing a distribution choice as much as a software platform.

What Forus Raised and Who Invested

The $150M Series C is new capital, not a restatement of the company's May disclosure. Forus said the latest round was led by Bain Capital Ventures, which has invested in the business since its early stage, while every existing institutional backer returned. Bloomberg and Reuters independently corroborated the amount, lead investor, valuation, and timing.

Capital accounting matters because the earlier announcement can be misread. When Tandem became Forus in May, the company said it had raised more than $160M in total. General Catalyst said it had led the Series A and was investing again in the Series B, but the public record reviewed for this article does not establish a $160M standalone Series B amount. The clean ledger is more than $160M cumulatively by May, $150M in new Series C financing in September, and more than $300M disclosed in total today.

The $3B valuation is approximately 3 times the $1B level Forbes reported in May. Forus has not disclosed whether the latest figure is pre-money or post-money, nor has it released ownership percentages, investor check sizes, or other transaction terms.

How the Forus Medication-Access Network Works

Forus operates after a clinician chooses a treatment. The platform assigns an AI agent to a prescription and works through insurance coverage, prior authorization and appeals, financial assistance, pharmacy selection, and fulfillment until the patient can begin therapy. The work spans structured systems and decidedly unstructured ones, including portals, documents, phone calls, and faxes.

That makes the agent's job different from producing a response in a chat window. Every patient brings a different clinical history, insurance plan, financial situation, drug, pharmacy, and set of eligibility rules. Forus says its agents combine clinical models, specialized sub-agents, and patterns learned from millions of cases to decide what must happen next and act across systems the company does not control.

Providers and patients use the product at no cost. That removes a procurement step from the side of the network where adoption begins, and it lets usage grow through physician workflows. Forus says the platform now supports millions of people across all 50 states and reaches patients in 85% of U.S. residential ZIP codes. Those are company-reported operating figures, not independently audited measures.

Why Biopharma Is the Commercial Side of the Network

The free provider and patient layer creates a broader view of where treatment access slows down. For life-sciences companies, that information can support trial recruitment, launch planning, physician outreach, coverage work, and analysis of why eligible patients do or do not begin a medicine. Forus says 9 of the top 15 global biopharma companies now work with the platform.

This is the economic wager behind the valuation. Providers contribute workflow adoption, patients create real cases, and each prescription expands the network's understanding of payer, pharmacy, affordability, and fulfillment combinations. Biopharma companies can pay for the ability to develop and launch medicines through that connected environment, although Forus has not disclosed pricing, contract length, customer concentration, or current revenue with the Series C.

The model also carries a demanding reliability standard. A recommendation engine can tolerate an irrelevant result. A medication-access agent has to preserve clinical context, submit accurate information, handle changing requirements, and leave enough evidence for people to understand what happened. The product becomes more valuable as the network grows, but the cost of a weak action also becomes more concrete.

The Founder Choice Behind the Distribution

Sahir Jaggi founded the company in 2023 after working on product and patient experience at Oscar Health. In an interview published by Forus, Jaggi said the business made no revenue for its first 2 years because the team prioritized building a network that physicians and patients would use. He described turning down commercial opportunities that would have pulled the company toward short-term revenue before the distribution layer was ready.

That decision explains why the Series C matters beyond runway. Free software can accelerate adoption, but it transfers the business burden elsewhere: the network must become useful enough to biopharma customers to support the cost of serving providers and patients at national scale. Investors are now assigning a $3B value to Forus's ability to hold both sides together.

The company has disclosed traction, but important pieces remain private. May reporting described company-supplied annualized revenue above $50M, while the latest announcement did not provide a newer figure. Public sources do not show revenue concentration, contract duration, margins, retention, or the economics of an individual drug-launch program.

What the Series C Changes

Forus plans to use the round to enter more specialties and care settings, expand the capabilities of its agent technology, and invest in headcount. The company says its ambition is to reach every doctor's office in the United States, a goal that would require product reliability across independent practices, specialty groups, health systems, payers, pharmacies, and drugmakers with different processes and incentives.

The network already has a visible path from provider adoption to commercial usefulness. General Catalyst wrote in May that Forus was supporting thousands of healthcare providers across all 50 states. The current announcement raises that picture to millions of people, 85% ZIP-code reach, and relationships with 9 of the top 15 biopharma companies, again based on company reporting.

DevCuration previously covered Forus's May funding and rebrand. The September financing is a distinct Series C event that gives the company more capital to turn early national reach into repeatable operating capacity.

What This Financing Signals for Healthcare AI

Healthcare AI attracts attention when it diagnoses, documents, or discovers. Forus is working in the less cinematic stretch after the clinical choice, where treatment can still be delayed by coverage, cost, routing, and administrative coordination. That is a large market precisely because no single participant controls the complete process.

The Series C suggests investors see value in companies that own cross-organization execution rather than one isolated task. Forus does not need to replace the payer, pharmacy, EHR, provider, or manufacturer to become important. It needs to make their handoffs work reliably enough that the prescription reaches the patient and the network becomes harder to operate without.

Forus now has the capital to test that model across more specialties, settings, and prescriptions. The consequences will arrive in ordinary places: a staff member who spends less time on the phone, a pharmacy that receives the right documentation, and a patient who starts the treatment a physician already chose.